FDA Approves Besifloxacin Drops for Treatment of Bacterial Conjunctivitis
June 1, 2009
Submit Comments
MedPage Today reported last week that the FDA had approved besifloxacin ophthalmic suspension 0.6% (Besivance) for the treatment of bacterial conjunctivitis. Besifloxacin is made by Bausch & Lomb.
The approval was based on clinical trials showing that patients using the drug had a faster rate of infection resolution than those treated with placebo. Fewer than 3% of patients in the trials reported adverse events, which included redness of the eyes, blurred vision, eye pain, irritation and itching, and headache.
Read the full article.
You might also enjoy...
- ISTA Pharmaceuticals’ Bepreve™ Receives FDA Approval For Ocular Itching Associated With Allergic Conjunctivitis
- ThromboGenics Completes Patient Enrollment in Microplasmin Trial
- Lux Biosciences’ Voclosporin Phase II/III Results Presented at AAO
- ISTA Pharmaceuticals Reports Results of Studies of REMURA(TM) Eye Drops for Dry Eye Disease
- ARVO Presentation Highlights: Uveitis, Lucentis, IOP, Retinal Detachment, Dry AMD, Bacterial Conjunctivitis, Glaucoma
Comments
Jump down to form below to submit your own comments
